{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T17:50:51Z","timestamp":1763747451238,"version":"build-2065373602"},"reference-count":32,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jem-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Emergency Medicine"],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1016\/j.jemermed.2015.04.019","type":"journal-article","created":{"date-parts":[[2015,10,22]],"date-time":"2015-10-22T22:44:13Z","timestamp":1445553853000},"page":"281-285","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Emergency Department Management of a Myasthenia Gravis Patient with Community-Acquired Pneumonia: Does Initial Antibiotic Choice Lead to Cure or Crisis?"],"prefix":"10.1016","volume":"50","author":[{"given":"Megan A.","family":"Van Berkel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer D.","family":"Twilla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bryan S.","family":"England","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jemermed.2015.04.019_bib1","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.jns.2007.04.045","article-title":"Myasthenic crisis: guidelines for prevention and treatment","volume":"261","author":"Jani-Acsadi","year":"2007","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.jemermed.2015.04.019_bib2","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/SMJ.0b013e31815d4398","article-title":"Myasthenia gravis crisis","volume":"101","author":"Bershad","year":"2008","journal-title":"South Med J"},{"key":"10.1016\/j.jemermed.2015.04.019_bib3","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1002\/j.1875-9114.1997.tb03085.x","article-title":"Drug-induced neuromuscular blockade and myasthenia gravis","volume":"17","author":"Barrons","year":"1997","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jemermed.2015.04.019_bib4","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1136\/jnnp.57.3.383","article-title":"Worsening of myasthenia gravis on treatment with imipenem\/cilastatin","volume":"57","author":"O'Riordan","year":"1994","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.jemermed.2015.04.019_bib5","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1093\/qjmed\/hcn152","article-title":"Myasthenia crisis","volume":"102","author":"Chaudhuri","year":"2009","journal-title":"Q J Med"},{"issue":"8590","key":"10.1016\/j.jemermed.2015.04.019_bib6","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/S0140-6736(88)91627-3","article-title":"Possible exacerbation of myasthenia gravis by ciprofloxacin","volume":"1","author":"Moore","year":"1988","journal-title":"Lancet"},{"key":"10.1016\/j.jemermed.2015.04.019_bib7","doi-asserted-by":"crossref","first-page":"839","DOI":"10.2165\/11593110-000000000-00000","article-title":"Fluoroquinolone-associated myasthenia gravis exacerbation. Evaluation of Postmarketing Reports from the US FDA Adverse Event Reporting System and Literature Review","volume":"34","author":"Jones","year":"2011","journal-title":"Drug Saf"},{"key":"10.1016\/j.jemermed.2015.04.019_bib8","first-page":"233","article-title":"Effect of different kinds of antibiotics on transmission function at the neuromuscular junction in mice with myasthenia gravis","volume":"9","author":"Deng","year":"2005","journal-title":"Chin J Clin Rehabil"},{"key":"10.1016\/j.jemermed.2015.04.019_bib9","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1212\/WNL.50.3.804","article-title":"Fluoroquinolone antibiotics block neuromuscular transmission","volume":"50","author":"Sieb","year":"1998","journal-title":"Neurology"},{"key":"10.1016\/j.jemermed.2015.04.019_bib10","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1001\/archinte.1997.00440250045006","article-title":"Drugs and myasthenia gravis","volume":"157","author":"Wittbrodt","year":"1997","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jemermed.2015.04.019_bib11","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0022-3476(05)81058-3","article-title":"Aggravation of myasthenia gravis by erythromycin","volume":"119","author":"Absher","year":"1991","journal-title":"J Pediatr"},{"key":"10.1016\/j.jemermed.2015.04.019_bib12","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1093\/clinids\/22.1.175","article-title":"A clarithromycin-induced myasthenic syndrome","volume":"22","author":"Pijpers","year":"1996","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jemermed.2015.04.019_bib13","article-title":"Aventis urges extreme caution with Ketek in patients with myasthenia gravis","volume":"36","author":"Reuters","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jemermed.2015.04.019_bib14","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1212\/01.wnl.0000247741.72466.8c","article-title":"Myasthenia gravis exacerbation or unmasking associated with telithromycin treatment","volume":"67","author":"Perrot","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.jemermed.2015.04.019_bib15","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1517\/14656566.9.2.267","article-title":"Ketolides: pharmcolotical provile and rational positioning in the treatment of respiratory tract infections","volume":"9","author":"Van Bambeke","year":"2008","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.jemermed.2015.04.019_bib16","unstructured":"US Food and Drug Administration. Labeling revision. June 29, 2006. Supplemental New Drug Application (NDA 21-144\/S-01). Ketek TM (telithromycin) [online]. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/appletter\/2006\/021144s011ltr.pdf. Accessed October 27,\u00a02014."},{"key":"10.1016\/j.jemermed.2015.04.019_bib17","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1086\/379617","article-title":"Telithromycin and myasthenia gravis","volume":"37","author":"Nieman","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jemermed.2015.04.019_bib18","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1056\/NEJMp078032","article-title":"The FDA and the case of Ketek","volume":"356","author":"Ross","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jemermed.2015.04.019_bib19","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1001\/archneur.1986.00520030045010","article-title":"Ampicillin may aggravate clinical and experimental myasthenia gravis","volume":"43","author":"Argov","year":"1986","journal-title":"Arch Neurol"},{"year":"2008","series-title":"Myasthenia gravis: A manual for the health care provider","key":"10.1016\/j.jemermed.2015.04.019_bib20"},{"issue":"5390","key":"10.1016\/j.jemermed.2015.04.019_bib21","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1136\/bmj.1.5390.1111-b","article-title":"Antibiotics in myasthenia gravis","volume":"1","author":"Hokkanen","year":"1964","journal-title":"Br Med J"},{"key":"10.1016\/j.jemermed.2015.04.019_bib22","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/j.1600-0404.1964.tb02758.x","article-title":"The aggravating effect of some antibiotics on the neuromuscular blockade in myasthenia gravis","volume":"40","author":"Hokkanen","year":"1964","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.jemermed.2015.04.019_bib23","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1001\/archneur.1968.00470340088008","article-title":"Myasthenia syndrome associated with antibiotics","volume":"18","author":"McQuillen","year":"1968","journal-title":"Arch Neurol"},{"key":"10.1016\/j.jemermed.2015.04.019_bib24","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1097\/01.CCM.0000239436.63452.81","article-title":"Acute neuromuscular weakness in the intensive care unit","volume":"34","author":"Maramattom","year":"2006","journal-title":"Crit Care Med"},{"key":"10.1016\/j.jemermed.2015.04.019_bib25","first-page":"1024","article-title":"Clinical approach to the weak patient in the intensive care unit","volume":"51","author":"Dhand","year":"2006","journal-title":"Resp Care"},{"year":"2013","series-title":"Product Information: TYGACIL(R) intravenous injection, tigecycline intravenous injection","key":"10.1016\/j.jemermed.2015.04.019_bib26"},{"issue":"Suppl. 2","key":"10.1016\/j.jemermed.2015.04.019_bib27","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1086\/511159","article-title":"Infectious Diseases Society of America\/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults","volume":"44","author":"Mandell","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jemermed.2015.04.019_bib28","unstructured":"Quality Net. Specifications Manual for National Hospital Inpatient\u00a0Quality Measures. Version 4.3b. Discharges 01-01-14 (1Q14) through 12-31-14 (4Q14). http:\/\/www.qualitynet.org\/dcs\/ContentServer?c=Page&pagename=QnetPublic%2FPage%2FQnetTier4&cid=1228773564870. Accessed October 28,\u00a02014."},{"key":"10.1016\/j.jemermed.2015.04.019_bib29","unstructured":"US Food and Drug Administration. FDA Drug Safety Communication: FDA warns of increased risk of death with IV antibacterial Tygacil (tigecycline) and approves new Boxed Warning. September 27, 2013. http:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm369580.htm. Accessed October 27,\u00a02014."},{"key":"10.1016\/j.jemermed.2015.04.019_bib30","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.ijantimicag.2013.01.020","article-title":"All-cause mortality imbalance in the tigecycline phase 3 and 4 clinical trials","volume":"41","author":"McGoven","year":"2013","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jemermed.2015.04.019_bib31","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1093\/cid\/cis397","article-title":"Imbalanced mortality evidence for tigecycline: 2011, the year of the meta-analysis","volume":"55","author":"Verde","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jemermed.2015.04.019_bib32","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1007\/s00134-014-3323-7","article-title":"Tigecycline use in critically ill patients: a multicentre prospective observational study in the intensive care setting","volume":"40","author":"Montravers","year":"2014","journal-title":"Intensive Care Med"}],"container-title":["The Journal of Emergency Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0736467915003662?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0736467915003662?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:33:31Z","timestamp":1760027611000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0736467915003662"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,2]]}},"alternative-id":["S0736467915003662"],"URL":"https:\/\/doi.org\/10.1016\/j.jemermed.2015.04.019","relation":{},"ISSN":["0736-4679"],"issn-type":[{"type":"print","value":"0736-4679"}],"subject":[],"published":{"date-parts":[[2016,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Emergency Department Management of a Myasthenia Gravis Patient with Community-Acquired Pneumonia: Does Initial Antibiotic Choice Lead to Cure or Crisis?","name":"articletitle","label":"Article Title"},{"value":"The Journal of Emergency Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jemermed.2015.04.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}